myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.
myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.
复制标题
DOI：
10.2337/dc12-1371
复制
发表时间：
2013-04
期刊：
影响因子：
16.2
通讯作者：
Di Benedetto A
中科院分区：
文献类型：
--
作者：
D'Anna R;Scilipoti A;Giordano D;Caruso C;Cannata ML;Interdonato ML;Corrado F;Di Benedetto A
验证补充肌醇可能减少有 2 型糖尿病家族史的孕妇妊娠期糖尿病 (GDM) 发病的假设。一项为期 2 年、前瞻性、随机、开放标签、安慰剂对照研究在父母患有 2 型糖尿病的怀孕门诊患者中进行，这些患者从妊娠第 3 个月末开始接受每天两次 2 g 肌醇加 200 µg 叶酸治疗（n = 110），而安慰剂组（n = 110）则每天仅接受 200 µg 叶酸治疗。主要结果指标是两组 GDM 的发生率。次要结局指标如下：巨大胎儿（>4,000 g）、妊娠高血压、早产、剖腹产、肩难产、新生儿低血糖和新生儿呼吸窘迫综合征的发生率。 GDM 诊断是根据国际糖尿病和妊娠研究组协会 (IADPSG) 的建议进行的。与安慰剂组相比，肌醇组 GDM 的发生率显着降低：分别为 6% 和 15.3%（P = 0.04）。在肌醇组中，GDM 风险发生率降低（比值比 0.35）。还强调了肌醇组中巨大胎儿的统计显着减少以及分娩时平均胎儿体重的显着减少。在其他次要结果指标中，组间没有差异。 有 2 型糖尿病家族史的孕妇补充肌醇可能会降低 GDM 的发生率和巨大胎儿的分娩。
To check the hypothesis that myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) onset in pregnant women with a family history of type 2 diabetes. A 2-year, prospective, randomized, open-label, placebo-controlled study was carried out in pregnant outpatients with a parent with type 2 diabetes who were treated from the end of the first trimester with 2 g myo-inositol plus 200 µg folic acid twice a day (n = 110) and in the placebo group (n = 110), who were only treated with 200 µg folic acid twice a day. The main outcome measure was the incidence of GDM in both groups. Secondary outcome measures were as follows: the incidence of fetal macrosomia (>4,000 g), gestational hypertension, preterm delivery, caesarean section, shoulder dystocia, neonatal hypoglycemia, and neonatal distress respiratory syndrome. GDM diagnosis was performed according to the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations. Incidence of GDM was significantly reduced in the myo-inositol group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04). In the myo-inositol group, a reduction of GDM risk occurrence was highlighted (odds ratio 0.35). A statistically significant reduction of fetal macrosomia in the myo-inositol group was also highlighted together with a significant reduction in mean fetal weight at delivery. In the other secondary outcome measures, there were no differences between groups. myo-Inositol supplementation in pregnant women with a family history of type 2 diabetes may reduce GDM incidence and the delivery of macrosomia fetuses.
登录
查看更多内容
影响因子：
2
作者：
D'Anna, R.;Di Benedetto, V.;Di Benedetto, A.
通讯作者：
Di Benedetto, A.
影响因子：
2
作者：
Genazzani, Alessandro D.;Lanzoni, Chiara;Jasonni, Valerio M.
通讯作者：
Jasonni, Valerio M.
影响因子：
6.7
作者：
Glueck, Charles J.;Pranikoff, Joel;Wang, Ping
通讯作者：
Wang, Ping
影响因子：
158.5
作者：
Nestler, JE;Jakubowicz, DJ;Allan, G
通讯作者：
Allan, G
影响因子：
3.5
作者：
Scioscia, M.;Kunjara, S.;Rademacher, T. W.
通讯作者：
Rademacher, T. W.